(HealthDay News) — Cryoablation seems to be a promising therapeutic option for early-stage invasive ductal breast cancers (IFDC), according to a study presented at the annual meeting of the American Society of Breast Surgeons, held from April 30–May 4 in Las Vegas.

Rache Simmons, MD, from the Weill Cornell Breast Center in New York City, and colleagues conducted a phase II trial to explore the effectiveness of cryoablation in the treatment of early-stage IFDC in 86 patients (87 breast cancers). A cryoprobe was inserted percutaneously into the targeted lesion and patients underwent ablation using a freeze-thaw-freeze cycle.

The researchers found that in pathologic assessment, cryoablation was successful in 69.0% of cancers, and residual IFDC and/or ductal carcinoma in situ (DCIS) were seen in 31.0% of cancers. Using a definition of successful cryoablation as no residual IFDC, 80.5% of cancers showed successful cryoablation. Using a definition of no residual IFDC/DCIS or enhancement on the post-ablation magnetic resonance imaging, 75.9% of breasts underwent successful cryoablation and 24.1% were failures.

“Clearly the benefits of cryoablation for breast cancer treatment are numerous. This study shows that it can be quite effective,” Simmons said in a statement. “Possibly some women may be able to take advantage of the technique within the next few years by participating in a trial of cryoablation used without follow-up surgery — perhaps even sooner.”

Press Release
More Information